|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||7.82 - 8.11|
|52 Week Range||4.77 - 9.95|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.29|
RESEARCH TRIANGLE PARK, N.C., April 24, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial.
BioCryst Pharmaceuticals (BCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
RESEARCH TRIANGLE PARK, N.C., April 01, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global Life.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its latestRead More...
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
—APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Full ZENITH-1 results confirm.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company is advancing BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, into Phase 1 clinical development in the second quarter of 2019 for the treatment of complement-mediated diseases. “Based on its outstanding preclinical profile, with high potency, excellent specificity for Factor D, complete suppression of complement-mediated hemolysis after oral dosing, and a wide safety margin, we are excited to advance oral BCX9930 into clinical development,” said Dr. William Sheridan, chief medical officer of BioCryst.
It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results and M&A news flow . View more earnings on XBI Now, here are the upcoming week's ...
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare.
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals, Inc. (BCRX) today reported additional topline data from the Phase 2 ZENITH-1 trial, including new data from the 250 mg and 500 mg dose cohorts. Data from the now complete trial confirm previously reported results showing a single dose of oral 750 mg BCX7353 was well-tolerated and superior to placebo (p
RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2018.
Biotech stocks got some reprieve in this week amid the release of earnings, clinical trial results presentations and positive FDA actions. Among the noteworthy developments of the week: The FDA panel ruling ...
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
On Nov. 6, detailing the company's third quarter earnings to a handful of analysts, BioCryst Pharmaceuticals' longtime CEO, Jon Stonehouse, said he sees 2019 to be a transformative year for the company.
—New loan facility increases to $50 million to further extend cash runway— —Additional $30 million available at company option following positive Phase 3 APeX-2 data—.
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present an abstract including results from the.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has appointed Steve Aselage to its board of directors. Mr. Aselage most recently served as chief executive officer of Retrophin Pharmaceuticals, a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease, which he joined in 2012. From 2005 to 2012, Mr. Aselage served as executive vice president and chief business officer of BioMarin.
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 37th Annual J.P. Morgan.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. The main goals of this trial are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in healthy subjects. BioCryst has global rights to galidesivir, a broad-spectrum antiviral drug in development to treat Marburg virus disease and Yellow Fever.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]